Screener
Xenon Pharmaceuticals XENE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's total liabilities?
- Xenon Pharmaceuticals (XENE) reported total liabilities of $53.38M in Q2 2026.
- How has Xenon Pharmaceuticals's total liabilities changed year-over-year?
- Xenon Pharmaceuticals's total liabilities increased by 32.4% year-over-year, from $40.3M to $53.38M.
- What is the long-term trend for Xenon Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's total liabilities has grown at a 23.6% compound annual growth rate (CAGR), from $17.83M to $51.4M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Xenon Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude